MK-1406: testing how the body handles two vs. three injections in healthy adults
Official title: A Randomized, Open Label, Parallel Group Phase 1 Study to Compare Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MK-1406 as Three Injections Compared With Two Injections in Healthy Adult Participants
Run by Merck Sharp & Dohme LLC · NCT07743151 · Data updated 2026-11-12
This early-phase study tests how MK-1406 behaves in healthy people when given as two injections versus three injections to see if it is safe and tolerable.
Quick facts
| Phase | Phase 1 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 64 Years |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | Merck Sharp & Dohme LLC Industry-sponsored |
| Locations | 7 sites (Hollywood, Florida and 6 other locations) |
| Status | Recruiting |
| Started | September 10, 2026 |
| Main results expected | February 5, 2027 |
| Study ends | February 5, 2027 |
| Registry record updated | October 27, 2026 |
| Trial ID | NCT07743151 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Healthy adults aged, typically, 18 and older with BMI 18.0–32.0 kg/m2 who have no significant medical history.
✕Probably not a fit
Individuals with major organ, endocrine, cardiovascular, hepatic, renal, or neurological conditions, or a history of cancer, may not benefit and are excluded.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a Phase 1 interventional trial enrolling healthy adults to compare the pharmacokinetics and safety of MK-1406 administered as two injections versus three injections. Participants will be in good health with BMI between 18.0 and 32.0 kg/m2 and will undergo procedures to receive MK-1406 under careful monitoring. The study aims to understand how the drug is processed in the body and identify any safety concerns or adverse effects. No efficacy outcomes in patients with diseases are expected or measured. Results will help determine appropriate dosing strategies for future studies.
Why it matters
Potential benefit: If successful, the findings could inform safe dosing approaches for MK-1406 in future research.
How similar studies have gone: Early PK/safety studies in healthy volunteers for similar agents have informed dosing; this study contributes to that foundational knowledge with MK-1406.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) 18.0 to 32.0 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * History of cancer (malignancy)
Where it's running
-
Research Centers of America ( Hollywood ) ( Site 0008)
Hollywood, Florida, United States Recruiting -
QPS-MRA, LLC ( Site 0007)
South Miami, Florida, United States Recruiting -
Parexel Baltimore EPCU ( Site 0010)
Baltimore, Maryland, United States Recruiting -
Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
Springfield, Missouri, United States Recruiting -
Hassman Research Institute Marlton Site ( Site 0001)
Marlton, New Jersey, United States Recruiting -
Velocity Clinical Research, Cleveland ( Site 0005)
Cleveland, Ohio, United States Recruiting
Show 1 more location
-
ICON Early Phase Services ( Site 0004)
San Antonio, Texas, United States Recruiting
Study contacts
- Study coordinator: Toll Free Number
- Email: Trialsites@msd.com
- Phone: 1-888-577-8839
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Do Quercefit® or Ubiqsome™ help with aging and metabolic health in adults 50–75?
This study tests whether Quercefit® or Ubiqsome™ can improve aging markers, blood sugar, and heart health in sedentary adults aged 50–75 compared with a placebo.
-
NVTIA Ergothioneine for Healthy Aging and Skin Health
This study tests whether taking NVTIA Ergothioneine daily for 12 weeks helps healthy adults age more gracefully and keeps skin looking and feeling better compared with a placebo.
-
Miricell supplementation and markers of healthy aging
This trial tests whether taking Miricell once daily for 12 weeks improves cellular health and brain/metabolic indicators in adults aged 40–70 compared with a placebo.
-
Does daily lean beef support brain health in older adults
In healthy adults aged 65 and up, this study tests whether eating lean beef every day for two weeks can influence brain health markers compared with a non-beef, protein-matched option.
-
Adaptive computerized training to boost thinking in healthy seniors and those with mild cognitive impairment
This study tests whether a computer-based training program can improve executive thinking in older adults, including those with mild cognitive impairment, and see if it also helps memory and well-being.
-
SHARP: Personalized Health and Behavior Plan to Lower Biological Age in Older Adults
A 12-month randomized trial tests whether a personalized health and behavior program can lower biological age and improve function in healthy adults over 50.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.